MX2014000286A - Uso de inhibidores hsp90 etiquetados. - Google Patents

Uso de inhibidores hsp90 etiquetados.

Info

Publication number
MX2014000286A
MX2014000286A MX2014000286A MX2014000286A MX2014000286A MX 2014000286 A MX2014000286 A MX 2014000286A MX 2014000286 A MX2014000286 A MX 2014000286A MX 2014000286 A MX2014000286 A MX 2014000286A MX 2014000286 A MX2014000286 A MX 2014000286A
Authority
MX
Mexico
Prior art keywords
hsp90
therapy
oncogenic
abundance
species
Prior art date
Application number
MX2014000286A
Other languages
English (en)
Other versions
MX347607B (es
Inventor
Tony Taldone
Gabriela Chiosis
Mary L Alpaugh
Eric M Gomes-Dagama
Monica L Guzman
Hongliang Zong
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of MX2014000286A publication Critical patent/MX2014000286A/es
Publication of MX347607B publication Critical patent/MX347607B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La descripción proporciona evidencia de que la abundancia de esta especie "HSP90 oncogénica" particular, que no se dictamina por la expresión HSP90 sola, predice la sensibilidad a terapia de inhibición HSP90, y de esta manera es un biomarcador para terapia de HSP90. La descripción también proporciona evidencia que identifica y mide la abundancia de esta especie HSP90 oncogénica en predicciones de tumores de respuesta a terapia HSP90. "HSP90 oncogénico" se define en la presente como la fracción HSP90 que representa una forma específica de tensión celular del complejo acompañante, que se expande y mantiene constitutivamente en el contexto de célula de tumor, y que puede ejecutar funciones necesarias para mantener el fenotipo maligno. Tales papeles no sólo son para regular el plegado de proteínas sobreexpresadas (es decir, HER2), mutadas (es decir, rnB-Raf) o quiméricas (es decir, Ver-Abl), sino también para facilitar el andamiaje y formación de complejo de moléculas involucradas en los complejos de señalización aberrantemente activados (es decir STATS, BCL6).
MX2014000286A 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados. MX347607B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08
PCT/US2012/045864 WO2013009657A1 (en) 2011-07-08 2012-07-06 Uses of labeled hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2014000286A true MX2014000286A (es) 2015-03-06
MX347607B MX347607B (es) 2017-05-04

Family

ID=47506428

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000286A MX347607B (es) 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados.
MX2014000292A MX2014000292A (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014000292A MX2014000292A (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90.

Country Status (14)

Country Link
US (4) US9555137B2 (es)
EP (3) EP3709022A1 (es)
JP (4) JP6054389B2 (es)
KR (2) KR102138218B1 (es)
CN (3) CN104081206B (es)
AU (3) AU2012282903A1 (es)
BR (1) BR112014000445A2 (es)
CA (2) CA2841069C (es)
DK (1) DK2729806T3 (es)
EA (1) EA201490230A1 (es)
ES (2) ES2624982T3 (es)
HK (1) HK1243175A1 (es)
MX (2) MX347607B (es)
WO (2) WO2013009657A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP6054389B2 (ja) 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたｈｓｐ９０阻害剤の使用
JP6678455B2 (ja) 2012-12-21 2020-04-08 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
AU2014306417C1 (en) 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof
WO2015038649A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
KR20180058824A (ko) 2015-10-05 2018-06-01 메모리얼 슬로안-케터링 캔서 센터 암 치료를 위한 합리적 병용 요법
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
CN111386351A (zh) * 2017-09-22 2020-07-07 华盛顿大学 细胞分子的原位组合标记
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US11493519B2 (en) 2019-02-08 2022-11-08 Dewpoint Therapeutics, Inc. Methods of characterizing condensate-associated characteristics of compounds and uses thereof
CN114173879A (zh) * 2019-05-15 2022-03-11 怀特黑德生物医学研究所 表征和利用药剂-凝聚物相互作用的方法
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
WO2022072694A1 (en) * 2020-10-02 2022-04-07 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
US20050074457A1 (en) * 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
WO2005012482A2 (en) * 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
EP1675861B1 (en) 2003-08-29 2015-12-23 Vernalis (R&D) Ltd. Pyrimidothiophene compounds
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
CN1922304A (zh) * 2003-10-31 2007-02-28 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP1946115A4 (en) * 2005-10-21 2009-12-02 Bayer Healthcare Llc METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
EP2034996A2 (en) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Triazole compounds that modulate hsp90 activity
AU2007269144B2 (en) * 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US8580519B2 (en) * 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
US20090092974A1 (en) * 2006-12-08 2009-04-09 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008128093A1 (en) * 2007-04-13 2008-10-23 Pharmacyclics, Inc. Calcium flux as a pharmacoefficacy biomarker for inhibitors of histone deacetylase
WO2009036092A2 (en) 2007-09-10 2009-03-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
AU2008310664A1 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CN102144163A (zh) 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
MX353747B (es) * 2009-08-17 2018-01-26 Memorial Sloan Kettering Cancer Center Star Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
ES2733131T3 (es) * 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
CA2779843A1 (en) 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
CN103582642B (zh) 2011-04-05 2021-05-11 索隆-基特林癌症研究协会 Hsp90抑制剂
BR112013027448A2 (pt) 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research terapia de combinação com hsp90
JP6054389B2 (ja) 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたｈｓｐ９０阻害剤の使用
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗

Also Published As

Publication number Publication date
ES2766623T3 (es) 2020-06-12
EP2729806A1 (en) 2014-05-14
CN109374889A (zh) 2019-02-22
CA2841173C (en) 2022-06-21
JP2014527620A (ja) 2014-10-16
US20210138091A1 (en) 2021-05-13
WO2013009655A3 (en) 2013-05-10
CA2841173A1 (en) 2013-06-17
JP2017121233A (ja) 2017-07-13
NZ620634A (en) 2016-07-29
AU2012282903A1 (en) 2014-02-13
AU2012282905A8 (en) 2017-08-31
KR20140075667A (ko) 2014-06-19
KR20170042805A (ko) 2017-04-19
EP2729806A4 (en) 2015-04-01
AU2012282905B2 (en) 2017-04-06
CN104081203A (zh) 2014-10-01
CN104081206A (zh) 2014-10-01
AU2012282905B8 (en) 2017-08-31
JP6054389B2 (ja) 2016-12-27
CN109374889B (zh) 2022-04-19
MX2014000292A (es) 2015-03-06
EP3709022A1 (en) 2020-09-16
DK2729806T3 (en) 2017-05-15
EA201490230A1 (ru) 2014-06-30
KR102138218B1 (ko) 2020-07-28
CN104081206B (zh) 2017-06-09
US20140242602A1 (en) 2014-08-28
BR112014000445A2 (pt) 2017-06-27
CN104081203B (zh) 2018-07-31
CA2841069C (en) 2021-11-23
US20140294725A1 (en) 2014-10-02
EP3208615B1 (en) 2019-10-09
EP2729806B1 (en) 2017-02-22
AU2017204369A1 (en) 2017-07-20
US20240058482A1 (en) 2024-02-22
AU2012282905A1 (en) 2014-02-13
EP3208615A2 (en) 2017-08-23
ES2624982T3 (es) 2017-07-18
JP2014525908A (ja) 2014-10-02
WO2013009655A2 (en) 2013-01-17
JP6218147B2 (ja) 2017-10-25
EP3208615A3 (en) 2017-11-01
CA2841069A1 (en) 2013-01-17
US9555137B2 (en) 2017-01-31
AU2017204369B2 (en) 2019-08-01
JP6662759B2 (ja) 2020-03-11
JP2019194232A (ja) 2019-11-07
WO2013009657A1 (en) 2013-01-17
US11607465B2 (en) 2023-03-21
HK1243175A1 (zh) 2018-07-06
KR102025142B1 (ko) 2019-09-26
MX347607B (es) 2017-05-04

Similar Documents

Publication Publication Date Title
MX347607B (es) Uso de inhibidores hsp90 etiquetados.
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
AU2012283775A8 (en) Inhibitors of Bruton's tyrosine kinase
WO2014160645A3 (en) Neuroendocrine tumors
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
GB201020995D0 (en) Biological materials and uses thereof
UA117121C2 (uk) Біспецифічне антитіло до egfr/с-мет
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
IN2012DN03012A (es)
SG195256A1 (en) Alkylamino bodipy dyes as selective fluorescent probes for proteins andmouse embryonic stem cells
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
TR201902439T4 (tr) Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri .
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2012154983A3 (en) Systems and methods for anti-pax8 antibodies
MX2013011354A (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
MX2014006187A (es) Composiciones y metodos para el analisis de cancer de prostata.
CO6721014A2 (es) Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2013002750A3 (en) Determining tumor origin

Legal Events

Date Code Title Description
FG Grant or registration